New injection aims to tame hormone chaos in kidney dialysis patients
NCT ID NCT06236295
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called SHR6508 in 303 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels get too high. The drug is given as an injection to help control these hormone levels and related minerals like calcium and phosphorus. The main goal is to check the drug's safety and how well it works over the long term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR6508 injection
- What this could lead to
- If successful, this could provide a new treatment option to better manage secondary hyperparathyroidism in people on dialysis, potentially reducing bone and heart problems.
- What could go wrong
- This is a Phase 2 trial with no placebo group, so results are preliminary. The drug may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk